I am pleased to introduce the final Fabry Outcome Survey (FOS) report for patients and caregivers, which is based on data collected within FOS from 5 October 2001 to 30 September 2022. The aim of this registry, funded by Takeda, was to collect information on patients with Fabry disease. [...]
Freeline has made the difficult decision to not progress our Fabry disease program further
April is Fabry Awareness Month! Join FIN in celebrating the #FabryHeroes!
Orphanet Journal of Rare Diseases recently published an in-depth history of the Sanofi Rare Disease Registries.
It is with great sadness that we learned of the passing of BongKi Lim, Fabry Korea's chairman for the past 22 years.
Evaluating the direct and indirect costs of Fabry disease
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease.
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease.
April 1st is International Fabry Women’s Day! Join us in celebrating this special day.
Putting people with Fabry first: a talent that Amicus Therapeutics and FIN share. This commonality has ensured a strong partnership, spanning more than 16 years. Amicus Therapeutics is a pharma industry leader advancing the professional field of patient advocacy; it develops and delivers medicine for people living with rare diseases. Jayne C. Gershkowitz, Chief [...]
